My Approach When Prescribing Here's my general framework not a rigid protocol, but a starting point for the conversation: I Tend to Start with Semaglutide When The patient has established cardiovascular disease (because of the SELECT trial data) Insurance covers semaglutide but not tirzepatide The patient has MASH/fatty liver disease Cost is the primary concern and semaglutide is more accessible I Tend to Start with Tirzepatide When Maximum weight loss is the primary goal The patient has type 2 diabetes (tirzepatide shows greater A1C reduction roughly 2.02.5% vs 1.02.0% for semaglutide) The patient has tried semaglutide with insufficient results Insurance covers both options equally Regardless of which medication we choose, I always emphasize that GLP-1 therapy is most effective when combined with nutritional counseling, physical activity, and behavioral support
Summary of BSH Cobalamin and Folate Guidelines pernicious-anaemia-society
The FDA allows compounding under certain circumstances, including when the drug is in shortage, as is the case for both semaglutide and tirzepatide
Frequently Asked Questions What weight loss was achieved with retatrutide in the phase 2 NEJM trial at 48 weeks
Yes, BPC-157 is commonly combined with testosterone therapy
Regular meal patterns help stabilise blood glucose levels and support the medication's mechanism of action